- 14
- Episodes
- Weekly
- Cadence
- 2026
- First episode
About GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA
The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.
- Publisher
- The GOG Foundation, Inc
- Category
- education · health & fitness
- Language
- en
- Explicit
- No
- First episode
- 9 Feb 2026
- Latest episode
- 16 Sept 2026
Latest episodes
14 episodes in the feed.
16 Sept 2026
Evolving Evidence and Treatment Strategies in Platinum-Resistant Ovarian Cancer: From Biology to Bedside
The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to listen to the Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside symposium podcast that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Friday, June 12, 2026. Platinum‑resistant ovarian cancer (PROC) remains a major therapeutic challenge due to modest survival outcomes and frequent treatment resistance. This CME session delivers a science‑forward, methodologic update designed to help clinicians interpret evolving evidence and educate the audience on thoughtful practice-based approach. Faculty will cover the current treatment landscape and survival benchmarks; mechanisms of resistance that inform next‑generation strategies; a masterclass in interpreting Phase 3 data (design, endpoints, and external validity); and equity and access considerations including biomarker testing logistics, clinical trial access, and shared decision‑making. Through a moderated panel, attendees will contextualize new evidence, anticipate how pending regulatory decisions may impact care, and identify research implications. This educational activity is supported by an independent medical education grant from Corcept Therapeutics
13 Aug 2026
Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer Enduring Educational Symposium that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sunday, June 14, 2026. This educational activity is supported by an independent medical education grant from GSK. Course Description The era of antibody–drug conjugates (ADCs) in gynecologic oncology have shifted from promise to intense competition. In ovarian and endometrial cancers, platforms targeting FRα, HER2/HER3, TROP2, B7-H4, CDH6, and NaPi2b are advancing rapidly. Mirvetuximab soravtansine has improved outcomes for FRα-positive ovarian cancer, while trastuzumab deruxtecan has extended HER2-directed therapy to certain endometrial tumors. Next-generation ADCs are improving antigen selection, internalization, payload potency, and linker stability to address antigen heterogeneity, resistance, and class-specific toxicities highlighted in recent studies. This symposium will provide a clear, evidence-based overview of the ADC landscape. Faculty will differentiate competing designs, evaluate key and emerging trial data, and offer practical guidance on sequencing, toxicity management, and biomarker-driven patient selection. The program will also highlight active trials and company strategies shaping future standards of care, ensuring participants are prepared to incorporate ADC advances into practice with confidence and clarity.
13 Aug 2026
The GOG Highlight Reel – July 2026
The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions will focus on emerging approved therapies and investigational agents, with an intent to provide insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the skills to navigate the latest oncology research and clinical care confidently. The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: Acrivon, AbbVie, AstraZeneca, Corcept Therapeutics, Eisai, Eli Lilly, Gilead, GSK, Karyopharm Therapeutics, Merck, Pfizer, Verastem
13 Aug 2026
Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC)
This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the current competitive landscape, new indications, and recent data surrounding folate receptor alpha–targeted therapies. The session will also look ahead to future developments, including the role of antibody–drug conjugates (ADCs) in low‑grade serous ovarian cancer, MEK inhibitors, and the significance of KRAS mutations. Additionally, the course will address the management of adverse events, dose modifications, and strategies to support patients experiencing treatment‑related reactions. A discussion of biomarkers and considerations for first‑line management of recurrent disease will help clinicians make informed, evidence‑based decisions.
13 Aug 2026
ctDNA-based MRD testing and monitoring in gynecologic cancers
Molecular residual disease (MRD) tracking via tumor-informed circulating tumor DNA (ctDNA) is redefining the surveillance and management paradigm in gynecologic oncology. This session delivers a data-driven evaluation of the evolving role of ctDNA in identifying subclinical recurrence and quantifying real-time treatment response across ovarian, uterine, and cervical cancers—frequently months ahead of traditional biomarkers and diagnostic imaging. Participants will examine the mechanistic basis of whole-genome and exome-based personalized assay designs, alongside the latest clinical datasets validating their prognostic utility. Through interactive, case-based reviews, faculty will demonstrate how longitudinal ctDNA tracking helps clarify complex clinical scenarios, such as predicting first-line maintenance benefit, identifying platinum sensitivity, and ruling out pseudoprogression during immunotherapy. The presentation will also address critical barriers to integration, including analytical limits of detection, Clonal Hematopoiesis of Indeterminate Potential (CHIP) filtering, and guideline implementation. To ensure a balanced perspective, this course contrasts ctDNA dynamics with traditional modalities, including CA-125 kinetics, investigative imaging cadence, and histopathological risk factors. Attendees will leave equipped to critically interpret molecular testing results and seamlessly integrate personalized genomic data into a multidisciplinary care framework.
13 Aug 2026
Precision Decision Making in Platinum Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care
Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and targeted therapies emerge. This 45‑minute case‑based educational program will provide clinicians with practical guidance on integrating folate receptor alpha (FRα) testing into real‑world decision‑making, alongside emerging considerations such as weekly paclitaxel and/or bevacizumab eligibility, PD-L1, HER2 status, and other biologic drivers. Through interactive discussion of patient cases led by two expert faculty, learners will explore how biomarker evaluation, clinical characteristics, and prior therapies influence treatment selection and sequencing, with an emphasis on optimizing outcomes in platinum‑resistant ovarian cancer.
29 May 2026
Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer: Charting the Course: Treatment Approaches for dMMR Endometrial Cancer
This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.
9 Feb 2026
Evidence Based Biomarker-Driven Advances in Ovarian & Endometrial Cancer: Equitable, Individualized and Accessible Care
This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience. The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for equitable and individualized care treatment plans that aim to improve patient outcomes. Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment. Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs. The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints. Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments. All content will be aligned with current regulatory guidelines and appropriate for independent medical education (IME), with a clear distinction between on-label use and emerging data requiring further validation.
9 Feb 2026
Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer First Installment
This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.
9 Feb 2026
Beyond the Image: New Opportunities in Gynecologic Cancer Testing
Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. This 90-minute course explores the evolving role of ctDNA in identifying disease recurrence and assessing treatment response—potentially earlier than imaging or traditional biomarkers. Participants will receive an in-depth overview of the biological basis of ctDNA detection, the current clinical evidence supporting its utility, and its integration into clinical workflows. Case-based discussions will illustrate real-world applications, showcasing how ctDNA can optimize decisions on surveillance and therapeutic strategy. The program will also critically assess limitations and challenges of ctDNA-based MRD testing, including issues with sensitivity, false positives, access, and cost. In alignment with a fair and balanced approach, the course will also explore other MRD detection modalities such as radiologic imaging, CA-125, and histopathology, highlighting comparative strengths and contexts for use. The program engages clinicians to learn how to interpret ctDNA MRD data and apply it effectively within a multidisciplinary care framework.
9 Feb 2026
The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers
This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning. Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making. This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear. This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.
9 Feb 2026
Global Perspective in Advanced, Recurrent Cervical Cancer: Resources, Opportunities and Access to Care.
This educational session explores the evolving global landscape of advanced and recurrent cervical cancer, with a focus on disparities in access to care and treatment innovations. Participants will review pivotal clinical trial data shaping current treatment paradigms, including the role of antibody-drug conjugates (ADCs) as a novel therapeutic option. Emphasis will be placed on how to compare and contrast global differences in treatment landscape and novel therapy implementation. Pearls for successful implementation of TV patient education, disease prevalence, and prevention strategies, with a spotlight on African regional statistics and global efforts to eliminate cervical cancer. The session will also highlight the World Health Organization’s approach to improving overall survival and discuss opportunities for healthcare professionals to contribute to global cervical cancer elimination initiatives.
9 Feb 2026
From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer
While antibody-drug conjugates (ADCs) have reshaped therapeutic paradigms, the latest clinical trial results reveal a broader array of opportunities, spanning novel mechanisms of action, immunotherapy-based combinations, and molecularly targeted strategies. Through rigorous analysis of newly presented efficacy and safety data, including key PFS/OS endpoints, expert faculty will provide context and interpretation to support real-world clinical decisions. Interactive discussion will center on how these innovations are poised to reshape treatment sequencing and improve patient outcomes. This dynamic symposium will spotlight the most compelling new data presented at 2025 oncology congresses, including ASCO, ESMO GYN, and ESMO—focusing on evolving strategies for the management of advanced, platinum-resistant high-grade epithelial ovarian cancer.
9 Feb 2026
A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies
This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventional therapies. Faculty will examine recent clinical trial data, discuss emerging best practices for biomarker testing and sequencing, and explore practical considerations for managing side effects and ensuring patient access to innovative treatments. Through real-world cases and interactive discussion, participants will gain insights to personalize care and optimize outcomes for patients living with recurrent LGSOC.
Host of GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.